← Back to Screener
Shuttle Pharmaceuticals Holdings, Inc. Common Stock (SHPH)
Price$0.99
Favorite Metrics
Price vs S&P 500 (26W)-83.87%
Price vs S&P 500 (4W)5.37%
Market Capitalization$5.70M
All Metrics
Book Value / Share (Quarterly)$1.13
P/TBV (Annual)1.06x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-9.06
Price vs S&P 500 (YTD)-47.47%
EPS (TTM)$-26.48
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-26.48
EPS (Annual)$-79.66
ROI (Annual)-578.78%
Cash / Share (Quarterly)$1.70
ROA (Last FY)-364.33%
EBITD / Share (TTM)$-11.23
ROE (5Y Avg)-348.67%
Cash Flow / Share (Annual)$-45.80
P/B Ratio4.09x
P/B Ratio (Quarterly)2.73x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-14.63x
ROA (TTM)-253.90%
EPS Incl Extra (Annual)$-79.66
Current Ratio (Annual)1.44x
Quick Ratio (Quarterly)1.07x
3-Month Avg Trading Volume1.86M
52-Week Price Return-84.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.45
52-Week High$11.25
EPS Excl Extra (Annual)$-79.66
26-Week Price Return-75.12%
Quick Ratio (Annual)1.25x
13-Week Price Return-32.89%
Total Debt / Equity (Annual)1.23x
Current Ratio (Quarterly)1.66x
Enterprise Value$6.121
Revenue / Employee (Annual)$0
Cash / Share (Annual)$12.00
3-Month Return Std Dev154.03%
Net Income / Employee (TTM)$-1
ROE (Last FY)-1288.00%
Net Interest Coverage (Annual)-257.20x
EPS Basic Excl Extra (Annual)$-79.66
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.30x
EPS Incl Extra (TTM)$-26.48
Receivables Turnover (Annual)0.00x
ROI (TTM)-370.82%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.56
Price vs S&P 500 (52W)-119.16%
Year-to-Date Return-43.33%
5-Day Price Return38.36%
EPS Normalized (Annual)$-79.66
ROA (5Y Avg)-167.42%
Month-to-Date Return50.27%
Cash Flow / Share (TTM)$-0.36
EBITD / Share (Annual)$-74.52
LT Debt / Equity (Annual)0.03x
ROI (5Y Avg)-201.22%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-26.48
P/TBV (Quarterly)1.18x
P/B Ratio (Annual)4.43x
Book Value / Share (Annual)$4.44
Price vs S&P 500 (13W)-35.76%
Beta1.33x
Revenue / Share (TTM)$0.00
ROE (TTM)-476.12%
52-Week Low$0.50
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SHPHShuttle Pharmaceuticals Holdings, Inc. Common Stock | — | — | — | — | $0.99 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Shuttle Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary technologies to enhance the efficacy of cancer treatments across multiple modalities, including radiation therapy, chemotherapy, and immunotherapy. The company's pipeline addresses limitations of current standard-of-care treatments while aiming to deliver safer, more reliable, and more accessible therapeutic options.